

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>35</u> , line <u>table</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ)	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b D-38124 Braunschweig Germany	
Date of deposit 06.10.2004	Accession Number DSM ACC2693 and DSM ACC2694
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input checked="" type="checkbox"/>	
1. Indications regarding the Accession Numbers of Deposits and 2. Indications relating to the Expert Solution in respect of the deposited biological material DSM ACC2693 and DSM ACC2694	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
CA (Canada), EP (European Patent), SG (Singapore)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input type="checkbox"/> This sheet was received with the international application	
Authorized officer	

For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
10 FEB 2005 (10.02.05)	
Authorized officer S. DESCLOUX	

C. ADDITIONAL INDICATIONS (additional sheet 1)

Applicants : F. HOFFMANN-LA ROCHE AG, et al.
Applicants file reference : 22250 WO-BUR
International application No. : PCT/EP2004/011860

**1. Indications Regarding the Accession Numbers of Deposits in Respect of Deposited
Biological Material**

The indications made below relate to the deposited cell cultures referred to in the description on page 35, table, and are required to be part of the description.

All mentioned cell lines were deposited under the Budapest Treaty with:
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ)
Mascheroder Weg 1b
D-38124 Braunschweig
Germany

<u>Date of deposit</u>	<u>Accession Number</u>	<u>Name, given by Depositor</u>
06.10.2004	DSM ACC2693	MAB <p27kip1>15
06.10.2004	DSM ACC2694	MAB <p27kip1>388

C. ADDITIONAL INDICATIONS (additional sheet 2)**2. Indications Relating to the Expert Solution in Respect of Deposited Biological Material Referred to in the Description**

The indications relating to deposited biological material are all contained in the description. The following additional indications are not required to be part of the description and should be treated as "separate indications." They relate to the expert solution.

The additional indications made below relate to the deposited biological material referred to as:

MAB <p27kip1>15 DSM ACC2693

MAB <p27kip1>388 DSM ACC2694

in the description on page 35.

The additional indications are:

For CA (Canada) designation:

In respect of the designation of Canada, samples of the deposited biological material will be made available until the grant of the Canadian patent, or until the date on which the application is refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, as provided in Rules 107 and 108 of the Patent Rules under the Canadian Patent Act, only by the issue of a sample to an independent expert nominated by the Commissioner (Rule 104(4))

For EP (European Patent) designation:

In respect of the designation of the EPO, samples of the deposited biological material will be made available until the publication of the mention of the grant of the European patent, or until 20 years from the date of filing if the application is refused or withdrawn or is deemed to be withdrawn, as provided in Rule 28(3) of the Implementing Regulations under the EPC, only by the issue of a sample to an expert nominated by requester (Rule 28(4) EPC).

For SG (Singapore) designation:

Applicants hereby give notice of our intention that samples of the above-identified culture shall be available only to experts in accordance with paragraph 3 of the Fourth Schedule to the Patents Rules 1995.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/011860

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/47 C12N9/16 G01N33/53 A61K38/43 C07K16/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHENG MANGENG ET AL: "The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts"</p> <p>EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 18, no. 6, 15 March 1999 (1999-03-15), pages 1571-1583, XP002273562</p> <p>ISSN: 0261-4189</p> <p>cited in the application</p> <p>the whole document</p> <p style="text-align: center;">----- -/--</p>	<p>1,2,5,6, 8,38-41</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

3 February 2005

Date of mailing of the international search report

14/02/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/011860

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LABAER JOSHUA ET AL: "New functional activities for the p21 family of CDK inhibitors" GENES AND DEVELOPMENT, vol. 11, no. 7, 1997, pages 847-862, XP0008028702 ISSN: 0890-9369 cited in the application the whole document	1,2,5,6, 8,38-41
A	WO 03/063581 A (MALEK NISAR P ;FRED HUTCHINSON CANCER RES CT (US); ROBERTS JAMES M) 7 August 2003 (2003-08-07) the whole document	
A	WO 96/14334 A (COX LYNNE SUZANNE ;LANE DAVID PHILIP (GB); UNIV DUNDEE (GB); WARBR) 17 May 1996 (1996-05-17) peptides 5 & 6figure 4	
A	WO 97/42222 A (LANE DAVID PHILIP ;CYCLACEL LTD (GB); BALL KATHRYN LINDSAY (GB)) 13 November 1997 (1997-11-13) Peptides 5 & 6figure 1	
A	WO 96/02140 A (SLOAN KETTERING INST CANCER ;KOFF ANDREW (US); MASSAGUE JOAN (US);) 1 February 1996 (1996-02-01) page 39, line 31	
A	MONTAGNOLI E A: "Ubiquitination of p27 is regulated by Cd-dependent phosphorylation and trimeric complex formation" GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, US, vol. 13, no. 9, 1 May 1999 (1999-05-01), pages 1181-1189, XP002151561 ISSN: 0890-9369 the whole document	
A	WO 02/090519 A (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 14 November 2002 (2002-11-14) the whole document	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/011860

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03063581	A	07-08-2003	WO 03063581 A2	07-08-2003
WO 9614334	A	17-05-1996	AT 191922 T	15-05-2000
			AU 694574 B2	23-07-1998
			AU 3811395 A	31-05-1996
			CA 2203909 A1	17-05-1996
			DE 69516416 D1	25-05-2000
			DE 69516416 T2	26-10-2000
			EP 0789711 A1	20-08-1997
			WO 9614334 A1	17-05-1996
			JP 10509312 T	14-09-1998
			US 6242201 B1	05-06-2001
WO 9742222	A	13-11-1997	AU 2707797 A	26-11-1997
			EP 0898580 A1	03-03-1999
			WO 9742222 A1	13-11-1997
			JP 2000513805 T	17-10-2000
			US 2004214765 A1	28-10-2004
WO 9602140	A	01-02-1996	US 5688665 A	18-11-1997
			AT 271129 T	15-07-2004
			AU 699969 B2	17-12-1998
			AU 1525195 A	01-08-1995
			AU 2770695 A	16-02-1996
			CA 2180570 A1	13-07-1995
			DE 69533255 D1	19-08-2004
			EP 0749442 A1	27-12-1996
			JP 9509311 T	22-09-1997
			WO 9518824 A1	13-07-1995
			WO 9602140 A1	01-02-1996
			US 6635450 B1	21-10-2003
			US 6316208 B1	13-11-2001
			US 6242575 B1	05-06-2001
			US 6355774 B1	12-03-2002
WO 02090519	A	14-11-2002	WO 02090519 A2	14-11-2002
			US 2003113897 A1	19-06-2003